US Food and Drug Administration (USFDA) has successfully completed Prior Approval Inspection (PAI) at Lupin’s Goa manufacturing facility without any observations. The inspection which started on July 17 concluded on July 21, 2017.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.